Update to Continued Dispensing Arrangements
Page last updated: 1 July 2022
From 1 July 2022, ongoing Continued Dispensing Arrangements have been expanded to include additional medicines groups to the statins and oral contraceptives, as recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) at its November 2021 meeting. The medicines recommended by the PBAC are predominantly for the management of chronic disease, such as asthma and other lung conditions, diabetes, and heart disease. The PBAC also endorsed the inclusion of medicines for the treatment of human immunodeficiency virus (HIV). For further information, please see the Pharmaceutical Benefits Scheme Continued Dispensing Arrangements web page. The Continued Dispensing Emergency Measure, initially put in place for the 2020 bushfire crisis and later extended to support the COVID-19 pandemic, concluded 30 June 2022.